SCHEDULE: Vestal Point Capital Acquires 7.8% Stake in Nurix Therapeutics

Vestal Point Capital, LP, through its managed funds, has disclosed beneficial ownership of 8,050,000 shares, representing 7.8% of Nurix Therapeutics, Inc. common stock.

Summary

• Vestal Point Capital, LP, acting as the investment manager for certain funds and a managed account, has reported beneficial ownership of 8,050,000 shares of Nurix Therapeutics, Inc. common stock.
• This holding represents 7.8% of the company's outstanding common stock as of June 30, 2026.
• Ryan Wilder, Chief Investment Officer and Managing Partner of Vestal Point Capital, LP, is also identified as a reporting person.
• The filing is an amendment to a Schedule 13G, indicating a passive investment approach rather than an attempt to influence control.
• The shares were acquired and are held in the ordinary course of business.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not controlling stake acquisition by an investment manager, indicating confidence in the company's prospects without aggressive control intentions.

Positives

• Significant investment by Vestal Point Capital, LP, suggests confidence in Nurix Therapeutics' long-term value.
• The 7.8% stake indicates a substantial shareholder, which can sometimes lead to increased board oversight or strategic input.
• The filing confirms the shares are held in the ordinary course of business, implying a standard investment strategy.

Negatives

• No specific negative financial or operational information is presented in this Schedule 13G filing.
• The passive nature of the filing (Schedule 13G) means it does not inherently signal any immediate catalyst for share price appreciation.

Risks

• As a Schedule 13G filing, it indicates a passive investment, meaning Vestal Point Capital is not actively seeking to control or influence the company's management or operations, which could limit its impact on strategic changes.
• The filing does not provide details on the specific investment strategy or the rationale behind acquiring this stake, leaving potential future shifts in strategy unaddressed.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or specific guidance regarding Nurix Therapeutics' future performance.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stakes acquired by investment managers in biotechnology companies like Nurix Therapeutics are common, reflecting the sector's potential for growth and volatility. This filing positions Vestal Point Capital as a notable institutional investor in the company.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by Vestal Point Capital may be viewed positively, indicating institutional interest, but the passive nature of the filing suggests no immediate impact on control or strategy.
• Management: The company's management will be aware of Vestal Point Capital's substantial holding, which could influence future strategic discussions or investor relations efforts.
• Creditors/Suppliers: No direct impact is indicated by this filing.

Next Steps

• Vestal Point Capital, LP will continue to hold its shares in Nurix Therapeutics, Inc. in the ordinary course of business.
• Further disclosures may be required if Vestal Point Capital's beneficial ownership changes significantly.

Key Dates

Recommendation

The filing indicates a significant passive investment by Vestal Point Capital, suggesting confidence in the company's underlying value. However, as a Schedule 13G, it does not signal an intent to influence control or drive immediate strategic changes. Therefore, a 'hold' recommendation is appropriate, pending further developments or operational updates from Nurix Therapeutics.

Keywords

Nurix Therapeutics, Vestal Point Capital, Schedule 13G, Beneficial Ownership, Investment Manager, Common Stock, Shareholder